论文部分内容阅读
目的探讨联合检测肿瘤相关物质联合检测试剂盒(TSGF)、CA125及CA199在卵巢癌诊断、疗效观察中的价值。方法采用化学分析技术检测TSGF,MEIA法检测CA125、CA199;检测我院2001～2006年期间200例血清中(包括卵巢癌110例,卵巢良性包块48例,正常妇女42例)TSGF、CA125及CA199值,并对卵巢癌患者进行治疗前后的TSGF、CA125、CA199值进行监测、随访。结果卵巢癌患者TSGF、CA125、CA199值及阳性检出率均高于良性肿瘤及正常妇女值,单独检测时敏感性分别为91.8%、77.3%、45.5%,联合测定TSGF和CA125,敏感性达92.0%,三项联合则敏感性达95.9%。结论认为联合测定TSGF、CA125、CA199有助于提高卵巢癌诊断的敏感性,同时对疗效观察及术后监测有重要价值。
Objective To explore the value of combined detection of tumor associated substances detection kit (TSGF), CA125 and CA199 in the diagnosis and treatment of ovarian cancer. Methods The serum levels of TSGF, CA125 and CA125 in 200 cases of ovarian cancer (including 110 cases of ovarian cancer, 48 cases of benign ovarian mass and 42 cases of normal women) in our hospital from 2001 to 2006 were detected by chemical analysis. CA199 value, and the treatment of ovarian cancer patients before and after treatment of TSGF, CA125, CA199 values were monitored and followed up. Results The values of TSGF, CA125, CA199 and the positive rate of TSGF, CA125 and CA199 in ovarian cancer patients were higher than those in benign tumors and normal women. The sensitivity of TSGF, CA125 and CA125 were 91.8%, 77.3% and 45.5% 92.0%, the three combined sensitivity of 95.9%. Conclusions The combined determination of TSGF, CA125 and CA199 is helpful to improve the sensitivity of ovarian cancer diagnosis and has important value in the observation of curative effect and postoperative monitoring.